← Browse by Condition
Medical Condition

stomach cancer

Total Trials
9
Recruiting Now
9
Trial Phases
Phase 1, Phase 2, Phase 3, Phase 1, Phase 2

Cancer clinical trials represent the largest single category of recruiting studies worldwide, encompassing everything from early-phase safety studies of novel oncology drugs to large Phase 3 comparisons against current standard-of-care chemotherapy regimens. The field has accelerated dramatically with the rise of immunotherapy, targeted therapies, and CAR-T cell treatments that have transformed outcomes for previously untreatable malignancies.

Trials include checkpoint inhibitors (PD-1/PD-L1 agents), KRAS inhibitors, ADC (antibody-drug conjugates), combination chemotherapy regimens, radiation protocols, and surgical technique comparisons. Many trials stratify by biomarker status (PD-L1 expression, TMB, MSI-H) to identify patients most likely to benefit.

The NCI, pharmaceutical sponsors, and academic cancer centers collectively fund thousands of oncology trials annually across every cancer type.

Frequently Asked Questions — stomach cancer Clinical Trials

How many clinical trials are currently recruiting for stomach cancer?
ClinicalMetric currently tracks 9 actively recruiting clinical trials for stomach cancer, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 9. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for stomach cancer?
stomach cancer research spans Phase 1 (3 trials), Phase 2 (4 trials), Phase 3 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a stomach cancer clinical trial?
Eligibility criteria for stomach cancer trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1
3
Phase 2
4
Phase 3
1
Top Sponsors
Washington University School of Medicine 1 trial
Ukrainian Society of Clinical Oncology 1 trial
Essen Biotech 1 trial
3H Pharmaceuticals Co., Ltd. 1 trial
Stanford University 1 trial

Recruiting Clinical Trials

NCT05187182 Phase 1
Recruiting

CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer

Enrollment
42 pts
Location
United States
Sponsor
Washington University School o...
View Trial →
NCT06028737 Phase 2, Phase 3
Recruiting

Total Neoadjuvant FLOT Chemotherapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer

Enrollment
150 pts
Location
Lithuania, Ukraine
Sponsor
Ukrainian Society of Clinical ...
View Trial →
NCT06532799 Phase 1, Phase 2
Recruiting

TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Stomach and Esophageal Cancer

Enrollment
75 pts
Location
China
Sponsor
Essen Biotech
View Trial →
NCT07354711 Phase 1, Phase 2
Recruiting

A First-in-human Study of 3H-10000 in Patients With Unresectable or Metastatic Solid Tumors

Enrollment
170 pts
Location
China
Sponsor
3H Pharmaceuticals Co., Ltd.
View Trial →
NCT01048281
Recruiting

Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma

Enrollment
100 pts
Location
United States
Sponsor
Stanford University
View Trial →
NCT05494060 Phase 2
Recruiting

XELOX Combined With Anlotinib and Penpulimab vs XELOX as Adjuvant Therapy in ctDNA Positive Gastric and Esophagogastric Junction Adenocarcinoma

Enrollment
80 pts
Location
China
Sponsor
The First Affiliated Hospital ...
View Trial →
NCT06263088
Recruiting

EQUITY GI: A Prospective Study to Enhance Quality, Inclusivity, and Trial Participation in Black Patients With Gastrointestinal Cancer.

Enrollment
200 pts
Location
United States
Sponsor
Case Comprehensive Cancer Cent...
View Trial →
NCT07310888
Recruiting

Robotic Gastrectomy With 5th Arm

Enrollment
10 pts
Location
Hong Kong, Japan
Sponsor
Chinese University of Hong Kon...
View Trial →
NCT07504367
Recruiting

Large Language Models Assist in Tumor MDT

Enrollment
60 pts
Location
China
Sponsor
Sun Yat-Sen Memorial Hospital ...
View Trial →
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology